{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:31:39Z","timestamp":1762939899235,"version":"3.45.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Guidelines recommend 5000U subcutaneous unfractionated heparin (UFH) for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized adults, but data comparing dosing frequencies is limited. This systematic review aimed to compare VTE and bleeding outcomes between twice daily (BID) and three times daily (TID) UFH regimens. A literature search was completed on 3\/7\/2024. The primary outcome was VTE occurrence (deep vein thrombosis (DVT) or pulmonary embolism (PE)). Secondary outcomes included bleeding events. Studies reporting any relevant outcomes were included, while non-human studies, reviews, non-English texts, and high VTE risk populations were excluded. Risk of bias was assessed using the Cochrane Risk-of-Bias or Newcastle-Ottawa Quality Assessment Form. Data were synthesized using Covidence and Excel. After screening, 24 studies were included: 9 observational and 15 randomized studies. Regimens with TID UFH had a 3.1% VTE occurrence (12 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009145\/4653) compared to 4.0% with BID regimens (9 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009218\/5426). Three times daily regimens demonstrated 4.8% DVTs (11 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009244\/5102) and 0.4% PEs (11 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924\/5372), compared to 9.7% DVTs (11 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009199\/2062) and 0.9% PEs (9 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200917\/1974) with BID regimens. Bleeding events occurred in 3.2% of patients with BID (9 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009196\/6080) and 4.3% with TID regimens (13 studies,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009393\/9044). Three times daily UFH regimens led to fewer VTE, DVT, and PE events but more bleeding compared to BID. Newer data suggests BID dosing may be more appropriate for general medical populations. Limitations include variability in data quality and publication dates. Registered with PROSPERO. No funding was received.\n                  <\/jats:p>","DOI":"10.1007\/s11239-025-03137-8","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:44:08Z","timestamp":1750916648000},"page":"851-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of venous thromboembolism (VTE) occurrence in hospitalized patients receiving prophylactic unfractionated heparin twice vs. three times daily"],"prefix":"10.1007","volume":"58","author":[{"given":"Stephanie H.","family":"Flint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley E.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly K.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya R.","family":"Chilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"11","key":"3137_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","volume":"10","author":"JA Heit","year":"2002","unstructured":"Heit JA, O\u2019Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med Jun 10(11):1245\u20131248. https:\/\/doi.org\/10.1001\/archinte.162.11.1245","journal-title":"Arch Intern Med"},{"key":"3137_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","volume":"137","author":"SD Grosse","year":"2016","unstructured":"Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE (2016) The economic burden of incident venous thromboembolism in the united states: A review of estimated attributable healthcare costs. Thromb Res Jan 137:3\u201310. https:\/\/doi.org\/10.1016\/j.thromres.2015.11.033","journal-title":"Thromb Res Jan"},{"issue":"11","key":"3137_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","volume":"8","author":"S Barbar","year":"2010","unstructured":"Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J Thromb Haemost Nov 8(11):2450\u20132457. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04044.x","journal-title":"J Thromb Haemost Nov"},{"issue":"22","key":"3137_CR4","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","volume":"27","author":"HJ Sch\u00fcnemann","year":"2018","unstructured":"Sch\u00fcnemann HJ, Cushman M, Burnett AE et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv Nov 27(22):3198\u20133225. https:\/\/doi.org\/10.1182\/bloodadvances.2018022954","journal-title":"Blood Adv Nov"},{"issue":"2 Suppl","key":"3137_CR5","doi-asserted-by":"publisher","first-page":"e195S","DOI":"10.1378\/chest.11-2296","volume":"141","author":"SR Kahn","year":"2012","unstructured":"Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians Evidence-Based clinical practice guidelines. Chest Feb 141(2 Suppl):e195S\u2013e226. https:\/\/doi.org\/10.1378\/chest.11-2296","journal-title":"Chest Feb"},{"key":"3137_CR6","unstructured":"Heparin Sodium Injection [package insert] (2024) Eatontown, NJ: Hikma Pharmaceuticals USA Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/017037s201lbl.pdf. Published October 24, Accessed November 1, 2024"},{"issue":"2","key":"3137_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1378\/chest.10-3084","volume":"140","author":"OJ Phung","year":"2011","unstructured":"Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest Aug 140(2):374\u2013381. https:\/\/doi.org\/10.1378\/chest.10-3084","journal-title":"Chest Aug"},{"key":"3137_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj Mar 29:372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj Mar"},{"key":"#cr-split#-3137_CR9.1","unstructured":"Lefebvre C, Glanville J, Briscoe S et al (2023) Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, eds. Cochrane handbook for systematic reviews of interventions. Cochrane"},{"key":"#cr-split#-3137_CR9.2","unstructured":"Accessed November 1, 2023. https:\/\/training.cochrane.org\/handbook\/current\/chapter-04"},{"issue":"4","key":"3137_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost Apr 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost Apr"},{"key":"3137_CR11","unstructured":"Covidence systematic review software. Veritas health innovation. www.covidence.org"},{"key":"3137_CR12","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"3137_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj Aug 28:366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"Bmj Aug"},{"issue":"1","key":"3137_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13643-024-02619-9","volume":"2","author":"C Forbes","year":"2024","unstructured":"Forbes C, Greenwood H, Carter M, Clark J (2024) Automation of duplicate record detection for systematic reviews: deduplicator. Syst Rev Aug 2(1):206. https:\/\/doi.org\/10.1186\/s13643-024-02619-9","journal-title":"Syst Rev Aug"},{"issue":"6","key":"3137_CR15","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/wnl.50.6.1683","volume":"50","author":"SI Kamran","year":"1998","unstructured":"Kamran SI, Downey D, Ruff RL (1998) Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. Neurology 50(6):1683\u20131688. https:\/\/doi.org\/10.1212\/wnl.50.6.1683","journal-title":"Neurology"},{"issue":"8","key":"3137_CR16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1592\/phco.26.8.1086","volume":"26","author":"CM Peterman","year":"2006","unstructured":"Peterman CM, Kolansky DM, Spinler SA (2006) Prophylaxis against venous thromboembolism in acutely ill medical patients: an observational study. Pharmacotherapy 26(8):1086\u20131090. https:\/\/doi.org\/10.1592\/phco.26.8.1086","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3137_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.genhosppsych.2014.06.007","volume":"36","author":"T Ishida","year":"2014","unstructured":"Ishida T, Suzuki T, Watanabe K, Sakurai H, Uchida H, Mimura M (2014) Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. Gen Hosp Psychiatry 36(6):690\u2013693. https:\/\/doi.org\/10.1016\/j.genhosppsych.2014.06.007","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"3137_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1310\/hpj5105-376","volume":"51","author":"J Beall","year":"2016","unstructured":"Beall J, Woodruff A, Hempel C, Wovkulich M, Zammit K (2016) Efficacy and safety of High-Dose subcutaneous unfractionated heparin prophylaxis for the prevention of venous thromboembolism in obese hospitalized patients. Hosp Pharm 51(5):376\u2013381. https:\/\/doi.org\/10.1310\/hpj5105-376","journal-title":"Hosp Pharm"},{"issue":"7","key":"3137_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.1775","volume":"36","author":"M Joy","year":"2016","unstructured":"Joy M, Tharp E, Hartman H et al (2016) Safety and efficacy of High-Dose unfractionated heparin for prevention of venous thromboembolism in overweight and obese patients. Pharmacotherapy 36(7):740\u2013748. https:\/\/doi.org\/10.1002\/phar.1775","journal-title":"Pharmacotherapy"},{"issue":"8","key":"3137_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1060028020974569","volume":"55","author":"T Regis","year":"2021","unstructured":"Regis T, Goriacko P, Ferguson N (2021) Safety of High-Dose unfractionated heparin for prophylaxis of venous thromboembolism in hospitalized obese patients. Ann Pharmacother 55(8):963\u2013969. https:\/\/doi.org\/10.1177\/1060028020974569","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3137_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0897190020961210","volume":"35","author":"MW Sorgi","year":"2022","unstructured":"Sorgi MW, Roach E, Bauer SR et al (2022) Effectiveness and safety of twice daily versus thrice daily subcutaneous unfractionated heparin for venous thromboembolism prophylaxis at a tertiary medical center. J Pharm Pract 35(2):190\u2013196. https:\/\/doi.org\/10.1177\/0897190020961210","journal-title":"J Pharm Pract"},{"issue":"5","key":"3137_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1358863x231189758","volume":"28","author":"AJ Jatis","year":"2023","unstructured":"Jatis AJ, Nei SD, Zieminski JJ, Mara K, Krauter AK (2023) Assessment of bleeding risk in low-weight patients receiving prophylactic subcutaneous unfractionated heparin. Vasc Med 28(5):443\u2013448. https:\/\/doi.org\/10.1177\/1358863x231189758","journal-title":"Vasc Med"},{"key":"3137_CR23","doi-asserted-by":"publisher","unstructured":"Kaylor DM, Wade RM, Chappell KB, Niemann MH, VanArsdale VM (2023) Venous thromboembolism prophylaxis with Enoxaparin versus unfractionated heparin in patients with low body weight. Plasmatology 17. https:\/\/doi.org\/10.1177\/26348535231156848","DOI":"10.1177\/26348535231156848"},{"issue":"7835","key":"3137_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S0140-6736(73)92597-X","volume":"2","author":"C Warlow","year":"1973","unstructured":"Warlow C, Beattle AG, Terry G (1973) A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 2(7835):934\u2013936","journal-title":"Lancet"},{"issue":"5","key":"3137_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1600-0404.1980.tb01498.x","volume":"61","author":"HJ Gelmers","year":"1980","unstructured":"Gelmers HJ (1980) Effects of low-dose subcutaneous heparin on the occurrence of deep vein thrombosis in patients with ischemic stroke. Acta Neurol Scand 61(5):313\u2013318. https:\/\/doi.org\/10.1111\/j.1600-0404.1980.tb01498.x","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"3137_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/003693308102600205","volume":"26","author":"JJ Belch","year":"1981","unstructured":"Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26(2):115\u2013117. https:\/\/doi.org\/10.1177\/003693308102600205","journal-title":"Scott Med J"},{"issue":"2","key":"3137_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ageing\/15.2.84","volume":"15","author":"ST McCarthy","year":"1986","unstructured":"McCarthy ST, Turner J (1986) Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 15(2):84\u201388. https:\/\/doi.org\/10.1093\/ageing\/15.2.84","journal-title":"Age Ageing"},{"issue":"3","key":"3137_CR28","first-page":"179","volume":"31","author":"K Zawilska","year":"1989","unstructured":"Zawilska K, Psuja P, Lewandowski K, Wr\u00f3z M (1989) Low-dose heparin in the prevention of thrombotic complications following acute myocardial infarction. Cor Vasa 31(3):179\u2013185","journal-title":"Cor Vasa"},{"issue":"3","key":"3137_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/0049-3848(90)90422-9","volume":"59","author":"J Harenberg","year":"1990","unstructured":"Harenberg J, Kallenbach B, Martin U et al (1990) Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 59(3):639\u2013650. https:\/\/doi.org\/10.1016\/0049-3848(90)90422-9","journal-title":"Thromb Res"},{"issue":"5","key":"3137_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.7326\/0003-4819-117-5-353","volume":"117","author":"AG Turpie","year":"1992","unstructured":"Turpie AG, Gent M, C\u00f4te R et al (1992) A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 117(5):353\u2013357. https:\/\/doi.org\/10.7326\/0003-4819-117-5-353","journal-title":"Ann Intern Med"},{"issue":"6","key":"3137_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ageing\/23.6.512","volume":"23","author":"R Dumas","year":"1994","unstructured":"Dumas R, Woitinas F, Kutnowski M et al (1994) A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age Ageing 23(6):512\u2013516. https:\/\/doi.org\/10.1093\/ageing\/23.6.512","journal-title":"Age Ageing"},{"issue":"4","key":"3137_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1055\/s-0038-1650617","volume":"76","author":"JF Bergmann","year":"1996","unstructured":"Bergmann JF, Neuhart E (1996) A multicenter randomized double-blind study of Enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 76(4):529\u2013534. https:\/\/doi.org\/10.1055\/s-0038-1650617","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"3137_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000217272","volume":"26","author":"E Lechler","year":"1996","unstructured":"Lechler E, Schramm W, Flosbach CW (1996) The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy\/safety profile of a low-molecular-weight heparin (enoxaparin). The prime study group. Haemostasis 26(Suppl 2):49\u201356. https:\/\/doi.org\/10.1159\/000217272","journal-title":"Haemostasis"},{"issue":"2","key":"3137_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1034\/j.1600-0404.2002.01215.x","volume":"106","author":"M Hillbom","year":"2002","unstructured":"Hillbom M, Eril\u00e4 T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M (2002) Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 106(2):84\u201392. https:\/\/doi.org\/10.1034\/j.1600-0404.2002.01215.x","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"3137_CR35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1067\/mhj.2003.189","volume":"145","author":"FX Kleber","year":"2003","unstructured":"Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW (2003) Randomized comparison of Enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614\u2013621. https:\/\/doi.org\/10.1067\/mhj.2003.189","journal-title":"Am Heart J"},{"issue":"1","key":"3137_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.str.0000195182.67656.ee","volume":"37","author":"H Diener","year":"2006","unstructured":"Diener H, Ringelstein EB, von Kummer R et al (2006) Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT trial. Stroke (00392499) 37(1):139\u2013144. https:\/\/doi.org\/10.1161\/01.str.0000195182.67656.ee","journal-title":"Stroke (00392499)"},{"issue":"9570","key":"3137_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/s0140-6736(07)60633-3","volume":"369","author":"DG Sherman","year":"2007","unstructured":"Sherman DG, Albers GW, Bladin C et al (2007) The efficacy and safety of Enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369(9570):1347\u20131355. https:\/\/doi.org\/10.1016\/s0140-6736(07)60633-3","journal-title":"Lancet"},{"issue":"6","key":"3137_CR38","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1538-7836.2010.03848.x","volume":"8","author":"H Riess","year":"2010","unstructured":"Riess H, Haas S, Tebbe U et al (2010) A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY study. J Thromb Haemost 8(6):1209\u20131215. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03848.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3137_CR39","doi-asserted-by":"publisher","first-page":"e2240373","DOI":"10.1001\/jamanetworkopen.2022.40373","volume":"1","author":"E Neeman","year":"2022","unstructured":"Neeman E, Liu V, Mishra P et al (2022) Trends and risk factors for venous thromboembolism among hospitalized medical patients. JAMA Netw Open Nov 1(11):e2240373. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.40373","journal-title":"JAMA Netw Open Nov"},{"issue":"12","key":"3137_CR40","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1253\/circj.CJ-17-0445","volume":"24","author":"Y Yamashita","year":"2017","unstructured":"Yamashita Y, Shiomi H, Morimoto T et al (2017) Asymptomatic lower extremity deep vein Thrombosis - Clinical characteristics, management strategies, and Long-Term outcomes. Circ J Nov 24(12):1936\u20131944. https:\/\/doi.org\/10.1253\/circj.CJ-17-0445","journal-title":"Circ J Nov"},{"issue":"6","key":"3137_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2146\/ajhp161057","volume":"15","author":"VO Popoola","year":"2018","unstructured":"Popoola VO, Lau BD, Tan E et al (2018) Nonadministration of medication doses for venous thromboembolism prophylaxis in a cohort of hospitalized patients. Am J Health Syst Pharm Mar 15(6):392\u2013397. https:\/\/doi.org\/10.2146\/ajhp161057","journal-title":"Am J Health Syst Pharm Mar"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03137-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:28:04Z","timestamp":1762939684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03137-8","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"11 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}